Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glargine and regular insulin vs NPH and regular insulin in Type 1 Diabetes
NCT05709938Phase 4Completed
- Sponsor
- King Edward Medical University
- Start
- Nov 2019
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine in type 1 diabetes mellitus (T1D) (2 arms), sponsored by King Edward Medical University. Primary endpoints: Hemoglobin A1c at 3 months, Hypoglycemia events at 3 months and 3 more. Started Nov 2019; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05709938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05709938.